Chad Reichard, MD
Urology · Carmel, INNPI 1417247479
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $270,598 of the $399,873 with a category attached, or 67.7%. 60 manufacturers reported payments, led by Merck at 45.3% of the total. 2025 is the largest year on record at $155,208, more than ten times the $629 reported in 2019. Among urology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 771 payments — averaging $518.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$181K
- Ferring Pharmaceuticals Inc.$100K
- Bayer$45K
- Johnson & Johnson$25K
- Pfizer$12K
- Novartis$8K
- plus $28K from 54 others
Across 89 payments — averaging $10,326 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$767K
- Merck$130K
- Ferring Pharmaceuticals AS$21K
- Novartis$727
What the payments were for
- Consulting fees$50,46213%
- Speaking & faculty fees$270,59868%
- Travel & lodging$56,44614%
- Food & beverage$22,0726%
- Education$2950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KEYTRUDA$174,722
- ADSTILADRIN$98,241
- Nubeqa$44,248
- RYBREVANT$13,522
- CARVYKTI$13,522
- PLUVICTO$8,049
- Erleada$6,176
- XTANDI$2,856
- TALZENNA$2,520
- JEVTANA$1,928
- Cysview$1,800
- IMFINZI$1,472
- LYNPARZA$1,183
- PROVENGE$840
- AKEEGA$508
- ANKTIVA$298
- Xofigo$268
- AquaBeam Robotic System$149
- SPEEDICATH$148
- GENERAL BPH$144
How this compares
$399,873 in reported general payments places this provider in the 95th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 227 | $3,199,742 |
| NubeqaDarolutamide | 139 | $1,703,079 |
| XtandiEnzalutamide | 116 | $1,250,731 |
| OrgovyxRelugolix | 245 | $656,404 |
| Abiraterone Acetate | 76 | $153,880 |
| GemtesaVibegron | 44 | $38,844 |
| MyrbetriqMirabegron | 36 | $21,023 |
| Tamsulosin Hcl | 166 | $2,369 |
| Prednisone | 99 | $692 |
| Finasteride | 24 | $490 |
| Oxybutynin Chloride ErOxybutynin Chloride | 22 | $385 |
| Cephalexin | 40 | $161 |
| Megestrol Acetate | 17 | $153 |
| Hydrocortisone | 17 | $133 |
| Levofloxacin | 17 | $85 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $25,357 | $3,199,742227 claims |
| BayerNubeqa | $45,361 | $1,703,079139 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $616 | $1,271,754152 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $1,016 | $695,248289 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $5,520 | $153,88076 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 272 urology providers in Indiana.
Other urology in Carmel
- Alexander TatemCarmel$418K
- Matthew MellonCarmel$159K
- Jason KovacCarmel$112K
- Kenneth NeyCarmel$55K
- Jeremiah DallmerCarmel$52K
- Scott FarnhamCarmel$30K
- Megan BockCarmel$28K
- Joshua RingCarmel$13K
- Clinton BahlerCarmel$11K
- Scott PikeCarmel$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.